Literature DB >> 10101215

The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.

K Augustyns1, G Bal, G Thonus, A Belyaev, X M Zhang, W Bollaert, A M Lambeir, C Durinx, F Goossens, A Haemers.   

Abstract

This review deals with the properties and functions of dipeptidyl peptidase IV (DPP IV, EC 3.4.14.5). This membrane anchored ecto-protease has been identified as the leukocyte antigen CD26. The following aspects of DPP IV/CD26 will be discussed : the structure of DPP IV and the new family of serine proteases to which it belongs, the substrate specificity, the distribution in the human body, specific DPP IV inhibitors and the role of CD26 in the intestinal and renal handling of proline containing peptides, in cell adhesion, in peptide metabolism, in the immune system and in HIV infection. Especially the latest developments in the search for new inhibitors will be reported as well as the discovery of new natural substrates for DPP IV such as the glucagon-like peptides and the chemokines. Finally the therapeutical perspectives for DPP IV inhibitors will be discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10101215

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  25 in total

1.  Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.

Authors:  Omprakash Tanwar; Girdhar Singh Deora; Lalima Tanwar; Gautam Kumar; Sridhara Janardhan; Mumtaz Alam; Mymoona Akhter
Journal:  J Mol Model       Date:  2014-04-01       Impact factor: 1.810

2.  Enzymatic properties of dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis and its participation in virulence.

Authors:  Y Kumagai; K Konishi; T Gomi; H Yagishita; A Yajima; M Yoshikawa
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms.

Authors:  Olgica Trenchevska; Matthew R Schaab; Randall W Nelson; Dobrin Nedelkov
Journal:  Methods       Date:  2015-03-07       Impact factor: 3.608

Review 4.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

5.  Histopathological studies on virulence of dipeptidyl aminopeptidase IV (DPPIV) of Porphyromonas gingivalis in a mouse abscess model: use of a DPPIV-deficient mutant.

Authors:  H Yagishita; Y Kumagai; K Konishi; Y Takahashi; T Aoba; M Yoshikawa
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.

Authors:  E Mannucci; L Pala; S Ciani; G Bardini; A Pezzatini; I Sposato; F Cremasco; A Ognibene; C M Rotella
Journal:  Diabetologia       Date:  2005-04-29       Impact factor: 10.122

7.  Molecular mechanism for connective tissue destruction by dipeptidyl aminopeptidase IV produced by the periodontal pathogen Porphyromonas gingivalis.

Authors:  Yumi Kumagai; Hisao Yagishita; Ayako Yajima; Tatsuya Okamoto; Kiyoshi Konishi
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

8.  DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.

Authors:  Nga N Ta; Corinne A Schuyler; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

9.  Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.

Authors:  Raylene A Reimer; Gary J Grover; Lee Koetzner; Roland J Gahler; Prateek Juneja; Michael R Lyon; Simon Wood
Journal:  J Nutr       Date:  2012-08-22       Impact factor: 4.798

10.  Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors.

Authors:  Yan-Ke Jiang
Journal:  J Mol Model       Date:  2010-01-13       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.